Casecontrol study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clin. transl. oncol. (Print)
; 26(3): 732-738, mar. 2024.
Artigo
em Inglês
| IBECS
| ID: ibc-230802
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Background Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management. Methods We designed a retrospective casecontrol study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment. Results 95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C). Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19. Conclusions Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Imunoterapia
/
Neoplasias Renais
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2024
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clínica Universidad de Navarra/Spain
/
HM Hospitales-Centro Integral Oncológico Clara Campal/Spain
/
Hospital Germá Trials I Pujol/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario La Paz/Spain
/
Hospital Universitario Marqués de Valdecilla/Spain
/
Hospital Universitario Ramón y Cajal/Spain
/
Universidad Francisco de Vitoria/Spain